Strategic expansion Faber Daeufer & Itrato has recently merged with Crowell & Moring LLP, signaling a strengthened capabilities in life sciences and emerging companies. This presents an opportunity to explore cross-sell or referral partnerships, joint engagements, and expanded service offerings to a larger client base and co-counsel arrangements.

Life sciences focus The firm specializes in corporate and transactional counsel for life sciences and high tech, with a track record across discovery to commercialization. Target potential clients in biotech, pharma, and medtech looking for experienced dealmakers, licensing, collaboration, and IP-intensive transactions.

Growth-driven clients Having advised over 800 companies, research institutions, and investors, the firm demonstrates breadth in high-stakes transactions. This can be positioned to attract early-stage startups seeking strategic guidance, late-stage companies pursuing complex licensing or M&A, and venture investors needing transactional support.

R&D talent & capabilities New hires in counsel and R&D transactional teams, plus collaboration with Danforth Advisors on contracting practices, indicate ongoing investment in technical expertise. This signals readiness to engage clients on sophisticated R&D agreements, milestone-based deals, and development-stage collaborations.

Regional positioning Based in Waltham, MA with a focus on U.S. life sciences and emerging tech markets, there is an opportunity to prospect regional biotech clusters, universities, and incubators around Boston and the Northeast for transactional and deal-structuring services.